期刊
JOURNAL OF CLINICAL VIROLOGY
卷 43, 期 4, 页码 361-366出版社
ELSEVIER
DOI: 10.1016/j.jcv.2008.08.008
关键词
Viral reactivation; HHV-6; Graft versus host disease; Hematopoietic stem cell transplantation; Immunology
类别
Human herpesvirus type 6 (HHV6) is known to reactivate after hematopoetic stern cell transplantation (HSCT) and has been suggested to be associated with increased mortality and severe clinical manifestations, including graft versus host disease (GvHD). The exact etiological role of HHV6 reactivation in increased morbidity and mortality after HSCT remains unclear, This review will focus Oil the Current available evidence of HHV6 reactivation after HSCT and its immuno-modulatory capacities, with particular emphasis oil the severe complication GvHD. At present, no effective specific antiviral treatment for HHV6 reactivation has been identified. The Currently available antiviral agents are Outlined, as well as possible future strategies for the treatment of HHV6 reactivation. Non-toxic, specific treatment or prevention of HHV6 reactivation might improve the safety and efficacy of the HSCT procedure. (c) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据